Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor-β Activation in Spontaneously Hypertensive Rats

被引:82
|
作者
Jose Zarzuelo, Maria [1 ]
Jimenez, Rosario [1 ,3 ]
Galindo, Pilar [1 ]
Sanchez, Manuel [1 ]
Nieto, Ana [4 ]
Romero, Miguel [1 ]
Maria Quintela, Ana [1 ]
Lopez-Sepulveda, Rocio [1 ]
Gomez-Guzman, Manuel [1 ]
Bailon, Elvira [1 ]
Rodriguez-Gomez, Isabel [2 ]
Zarzuelo, Antonio [1 ,5 ]
Galvez, Julio [1 ,5 ]
Tamargo, Juan [6 ]
Perez-Vizcaino, Francisco [6 ,7 ,8 ]
Duarte, Juan [1 ]
机构
[1] Univ Granada, Sch Pharm, Dept Pharmacol, E-18071 Granada, Spain
[2] Univ Granada, Sch Med, Dept Physiol, E-18071 Granada, Spain
[3] Ctr Biomed Res, Granada, Spain
[4] Anapath, Anat Pathol Lab, Granada, Spain
[5] Ciber Enfermedades Hepat & Digest, Madrid, Spain
[6] Univ Complutense Madrid, Sch Med, Dept Pharmacol, Madrid, Spain
[7] Ciber Enfermedades Resp, Madrid, Spain
[8] Hosp Clin San Carlos, Inst Invest Sanitaria, Madrid, Spain
关键词
PPAR beta/delta; spontaneously hypertensive rat; endothelial dysfunction; NADPH oxidase; regulators of G protein-coupled signaling proteins; PROTEIN-KINASE-C; ANGIOTENSIN-II; OXIDATIVE STRESS; FATTY-ACID; PPAR-ALPHA; KAPPA-B; EXPRESSION; ENDOTHELIN-1; HEART; HYPERTROPHY;
D O I
10.1161/HYPERTENSIONAHA.111.174490
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta (PPAR beta) has been shown to improve insulin resistance and plasma high-density lipoprotein levels, but nothing is known about its effects in genetic hypertension. We studied whether the PPAR beta agonist GW0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHRs). The rats were divided into 4 groups, Wistar Kyoto rat-control, Wistar Kyoto rat-treated (GW0742, 5 mg . kg(-1) . day(-1) by oral gavage), SHR-control, and SHR-treated, and followed for 5 weeks. GW0742 induced a progressive reduction in systolic arterial blood pressure and heart rate in SHRs and reduced the mesenteric arterial remodeling, the increased aortic vasoconstriction to angiotensin II, and the endothelial dysfunction characteristic of SHRs. These effects were accompanied by a significant increase in endothelial NO synthase activity attributed to upregulated endothelial NO synthase and downregulated caveolin 1 protein expression. Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1 beta, interleukin 6, or intercellular adhesion molecule 1. None of these effects were observed in Wistar Kyoto rats. PPAR beta activation, both in vitro and in vivo, increased the expression of the regulators of G protein-coupled signaling proteins RGS4 and RGS5, which negatively modulated the vascular actions of angiotensin II. PPAR beta activation exerted antihypertensive effects, restored the vascular structure and function, and reduced the oxidative, proinflammatory, and proatherogenic status of SHRs. We propose PPAR beta as a new therapeutic target in hypertension. (Hypertension. 2011;58:733-743.)
引用
收藏
页码:733 / U437
页数:23
相关论文
共 50 条
  • [41] Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Lin Wang
    Yin Cai
    Liguo Jian
    Chi Wai Cheung
    Liangqing Zhang
    Zhengyuan Xia
    Cardiovascular Diabetology, 20
  • [42] Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators
    Han, SH
    Quon, MJ
    Koh, KK
    HYPERTENSION, 2005, 46 (05) : 1086 - 1092
  • [43] Lipid metabolism:: peroxisome proliferator-activated receptor-α and atherosclerosis
    van Greevenbroek, MMJ
    van der Kallen, CJH
    CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (02) : 223 - 225
  • [44] The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
    Li, Jingjing
    Guo, Chuanyong
    Wu, Jianye
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2619 - 2628
  • [45] Role of Peroxisome Proliferator-Activated Receptor-γ in Atherosclerosis - An Update
    Wang, Nanping
    Yin, Ruiying
    Liu, Yan
    Mao, Guangmei
    Xi, Fang
    CIRCULATION JOURNAL, 2011, 75 (03) : 528 - 535
  • [46] Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis
    Yang, Liu
    Chan, Che-Chang
    Kwon, Oh-Sang
    Liu, Songling
    McGhee, Jason
    Stimpson, Stephen A.
    Chen, Lihong Z.
    Harrington, W. Wallace
    Symonds, William T.
    Rockey, Don C.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 291 (05): : G902 - G911
  • [47] Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling
    Adamson, DJA
    Frew, D
    Tatoud, R
    Wolf, CR
    Palmer, CNA
    MOLECULAR PHARMACOLOGY, 2002, 61 (01) : 7 - 12
  • [48] Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation
    Bishop-Bailey, David
    Bystrom, Jonas
    PHARMACOLOGY & THERAPEUTICS, 2009, 124 (02) : 141 - 150
  • [49] Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Wang, Lin
    Cai, Yin
    Jian, Liguo
    Cheung, Chi Wai
    Zhang, Liangqing
    Xia, Zhengyuan
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [50] Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis
    Lee, CH
    Evans, RM
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (08): : 331 - 335